Eli Lilly reports fourth-quarter earnings and revenue that handily top expectations and issues solid guidance. ...

Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025.Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The pharmaceutical giant anticipates its 2026 revenue will come in between $80 billion and $83 billion. Analysts expected revenue of $77.62 billion, according to LSEG. Lilly also expected adjusted ea ...

Feb 4 (Reuters) - Eli Lilly forecast 2026 profit above Wall Street estimates on ​Wednesday, betting on surging demand for ‌its obesity drugs as the world's most valuable ‌drugmaker prepares to launch its oral weight-loss pill later this year. Shares of the company rose nearly 7% in premarket trading. Lilly last ⁠year became the ‌first pharmaceutical company to hit a $1 trillion valuation, driven by the ‍popularity of its blockbuster weight-loss drug, Zepbound, and a rapidly expanding obesity market tha ...

Eli Lilly forecast 2026 profit above Wall Street estimates on Wednesday, as it expects strong demand for its blockbuster weight-loss and diabetes drugs, Zepbound and Mounjaro, to offset pricing pressures in the U.S., its largest market. ...

风险提示及免责条款 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何 意见、观点或结论是否符合其特定状况。据此投资，责任自负。 礼来第四季度营收为192.9亿美元，同比增长43%。预计全年营收为800亿至830亿美元，市场预期为 777.1亿美元。 ...

Core Insights - Eli Lilly and Company reported significant financial growth in Q4 2025, with a 43% increase in revenue to $19.3 billion compared to Q4 2024, driven by strong volume growth from key products like Mounjaro and Zepbound [3][4][8] - The company provided optimistic financial guidance for 2026, projecting revenue between $80 billion and $83 billion and non-GAAP EPS in the range of $33.50 to $35.00 [25][26] Financial Results - Q4 2025 revenue reached $19.3 billion, a 43% increase from $13.5 billion in Q4 2024, with a 46% increase in volume offset by a 5% decrease in realized prices [4][8] - Net income for Q4 2025 was $6.6 billion, up 50% from $4.4 billion in Q4 2024, with reported EPS increasing by 51% to $7.39 [11][15] - Non-GAAP net income for Q4 2025 was $6.8 billion, a 41% increase from $4.8 billion in Q4 2024, with non-GAAP EPS rising by 42% to $7.54 [14][37] Revenue Breakdown - U.S. revenue increased by 43% to $12.9 billion, driven by a 50% increase in volume, primarily from Zepbound and Mounjaro [5][8] - International revenue also rose by 43% to $6.4 billion, with a 38% increase in volume, largely attributed to Mounjaro [6][8] Key Product Performance - Mounjaro revenue surged by 110% to $7.4 billion in Q4 2025, with U.S. revenue at $4.1 billion, reflecting strong demand [18] - Zepbound revenue increased by 123% to $4.3 billion in Q4 2025, driven by heightened demand [19] - Verzenio revenue saw a modest increase of 3% to $1.6 billion, with U.S. revenue declining by 4% [20] Regulatory and Pipeline Developments - Regulatory advancements included FDA approvals for Kwikpen for tirzepatide and expanded indications for Jaypirca, along with submissions for orforglipron for obesity [8][21] - Positive Phase 3 trial results were reported for Taltz and Zepbound in treating psoriatic arthritis and obesity [23] Operational Expenses - Research and development expenses rose by 26% to $3.8 billion, representing 20% of revenue, reflecting ongoing investments in the product pipeline [9] - Marketing, selling, and administrative expenses increased by 29% to $3.1 billion, driven by promotional efforts for product launches [10] Gross Margin and Tax Rate - Gross margin for Q4 2025 was $15.9 billion, a 43% increase, with a gross margin percentage of 82.5% [9][12] - The effective tax rate for Q4 2025 was 19.7%, up from 12.5% in Q4 2024, influenced by a less favorable jurisdictional mix of earnings [10][13]

Market Overview - U.S. stock futures showed mixed performance following a negative close on Tuesday, with major benchmark indices fluctuating [1] - The 10-year Treasury bond yielded 4.27%, while the two-year bond was at 3.58%, indicating market expectations for interest rates [2] Index Performance - Dow Jones increased by 0.12%, S&P 500 by 0.061%, while Nasdaq 100 decreased by 0.093% and Russell 2000 rose by 0.38% [3] Stocks in Focus - Advanced Micro Devices (AMD) saw a premarket decline of 7.63% despite better-than-expected fourth-quarter results, maintaining a strong price trend overall [6] - Enphase Energy (ENPH) surged by 23.39% after beating earnings estimates, with a strong price trend across all time frames [7] - Eli Lilly (LLY) was down by 0.046% ahead of its earnings report, with analysts expecting earnings of $6.93 per share on revenue of $17.93 billion [7] Sector Performance - Information technology, communication services, and health care sectors led losses in the S&P 500, while materials and energy shares finished higher [8] Analyst Insights - Jeremy Siegel expressed a positive outlook on the economy and stock market, citing reduced political uncertainties and the nomination of Kevin Warsh for Federal Reserve Chair as beneficial [9] - Siegel noted that fourth-quarter GDP estimates have moderated but growth remains solid, and he is not concerned about recent inflation related to tariffs [10] - He predicts a shift in the AI narrative, emphasizing that 2023 will favor firms that utilize AI for productivity over those that merely sell AI tools [11] Upcoming Economic Data - Investors are anticipating Fed Governor Lisa Cook's speech and the release of January's ADP Employment data [12] Commodities and Global Markets - Crude oil futures rose by 0.49% to approximately $63.53 per barrel, while Gold Spot increased by 2.12% to around $5,052.03 per ounce [13] - Asian markets closed higher, with notable gains in indices across India, Hong Kong, China, Australia, Japan, and South Korea [14]

Core Insights - Eli Lilly is positioned to potentially overtake Novo Nordisk in the weight-loss drug market following disappointing results from Novo, with investor confidence in Lilly's GLP-1 treatments growing significantly [1][2][3] Group 1: Eli Lilly's Performance - Eli Lilly's GLP-1 treatments for diabetes and weight loss saw accelerated sales growth in 2025, leading to a 39% increase in share prices [2] - Analysts forecasted Eli Lilly to achieve approximately $17.9 billion in revenue for the most recent quarter, reflecting a 32% increase year-over-year [2] - The company is expected to introduce a new weight-loss pill, orforglipron, to compete with Novo's offerings [6] Group 2: Novo Nordisk's Challenges - Novo Nordisk reported a decline in sales and operating profit expectations for the year, projecting a fall between 5% and 13% due to increased competition and lower US prices [3] - The company's shares dropped over 14.6% following the announcement of its disappointing results [3] - Novo's exclusivity for its drugs in key markets like Brazil, Canada, and China has ended, further impacting its sales outlook [3] Group 3: Market Dynamics - The weight-loss drug market is facing downward pressure from the proliferation of cheaper generic drugs and increased competition, leading to revised revenue forecasts [4] - Jefferies reduced its weight-loss market forecast by 20%, estimating a peak of $80 billion by 2030, down from over $100 billion [4] - Goldman Sachs also lowered its market estimate from $130 billion to $105 billion [4] Group 4: Future Prospects - Eli Lilly's pipeline includes seven phase 3 trials for its next-generation obesity drug, retatrutide, expected to conclude in 2026, targeting weight management, Type 2 diabetes, and cardiovascular issues [6] - Analysts from UBS have identified Lilly as "the best growth story for 2026-2030" based on its trajectory and pipeline developments [6]

Market Overview - The three major U.S. stock indices closed lower, with the Dow Jones down 0.34%, the Nasdaq down 1.43%, and the S&P 500 down 0.83% [1] - Popular technology stocks experienced declines, with Broadcom falling over 3%, and Microsoft, Nvidia, and Meta each dropping over 2% [1] Sector Performance - The rare earth, non-ferrous metals, and precious metals sectors saw significant gains, with gold resources rising over 20%, Southern Copper up over 11%, Americas Silver up over 8%, and Pan American Silver up over 5% [1] - Conversely, application software, cryptocurrency, and weight loss drug stocks faced notable declines, with Novo Nordisk down over 14%, Coinbase and Circle each down over 4%, and Eli Lilly and Pfizer each down over 3% [1] Notable Company Movements - Walmart's stock increased by 2.94%, marking its market capitalization surpassing the $1 trillion milestone for the first time [1] - The Nasdaq Golden Dragon China Index fell by 0.94%, with significant declines in popular Chinese stocks such as Daqo New Energy down 5.6%, Bilibili down 4%, and Kingsoft Cloud down 3.5% [1] - Alibaba dropped 2.9%, while NIO rose 0.8%, Pony.ai increased by 2%, Huazhu up 2.2%, New Oriental up 2.3%, Li Auto up 2.7%, Canadian Solar up 4.1%, and Xpeng up 4.3% [1]

Group 1 - The Chinese central bank announced a reverse repurchase operation of 800 billion yuan to maintain liquidity in the banking system, with a term of 3 months [2] - The Shanghai Stock Exchange reported a significant increase in new A-share accounts, with 4.9158 million new accounts opened in January 2026, a month-on-month increase of approximately 89% and a year-on-year increase of about 213% [2] - The Paris prosecutor's office conducted a search of the office of the social media platform X, owned by Elon Musk, as part of an investigation into cybercrime [3] Group 2 - Major U.S. stock indices experienced declines, with the Dow Jones down 0.34%, S&P 500 down 0.84%, and Nasdaq down 1.43%, nearly erasing gains made since the beginning of the year [3][4] - Large technology stocks faced pressure, with Nvidia down 2.84%, Microsoft down 2.87%, and Amazon down 1.79% [4] - The Nasdaq Golden Dragon China Index fell by 0.94%, with Alibaba down 2.81% and Tencent Holdings ADR down 3.33% [4] Group 3 - Commodity markets saw a rebound in gold and silver prices after two days of significant declines, with spot gold rising 5.2% to $4,906.82 per ounce [5] - Crude oil prices slightly rebounded, with WTI crude oil futures increasing by 1.72% to $63.21 per barrel [5] - Several companies announced significant developments, including a change in controlling shareholder for Jiatang and a fundraising plan for Xuguang Electronics [5]